AbCellera (ABCL) announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, an investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis. ABCL575 is an Fc-silenced, half-life extended antibody that targets OX40 ligand. The randomized, placebo-controlled, double-blind study will assess safety and tolerability in healthy participants. Data from this study is expected in mid 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights
- AbCellera price target raised to $7 from $5 at BMO Capital
- AbCellera Biologics Advances Clinical Trials and Revenue Growth
- AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating
- AbCellera Biologics Reports Q2 2025 Financial Results